Thermo Fisher Scientific Inc. (NYSE:TMO) is Waters Parkerson & CO. LLC’s Largest Position

Waters Parkerson & CO. LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 0.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 168,750 shares of the medical research company’s stock after buying an additional 302 shares during the period. Thermo Fisher Scientific accounts for about 5.1% of Waters Parkerson & CO. LLC’s holdings, making the stock its largest holding. Waters Parkerson & CO. LLC’s holdings in Thermo Fisher Scientific were worth $85,416,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Savant Capital LLC grew its position in Thermo Fisher Scientific by 0.5% during the 4th quarter. Savant Capital LLC now owns 3,627 shares of the medical research company’s stock worth $1,997,000 after purchasing an additional 18 shares during the last quarter. 1776 Wealth LLC raised its stake in shares of Thermo Fisher Scientific by 2.4% during the 4th quarter. 1776 Wealth LLC now owns 799 shares of the medical research company’s stock worth $440,000 after buying an additional 19 shares during the last quarter. Dover Advisors LLC lifted its stake in Thermo Fisher Scientific by 0.6% in the 2nd quarter. Dover Advisors LLC now owns 3,168 shares of the medical research company’s stock valued at $1,654,000 after buying an additional 20 shares in the last quarter. Westbourne Investment Advisors Inc. raised its stake in Thermo Fisher Scientific by 3.6% in the 2nd quarter. Westbourne Investment Advisors Inc. now owns 568 shares of the medical research company’s stock valued at $296,000 after purchasing an additional 20 shares during the last quarter. Finally, Klingman & Associates LLC lifted its position in Thermo Fisher Scientific by 5.0% during the second quarter. Klingman & Associates LLC now owns 439 shares of the medical research company’s stock worth $229,000 after buying an additional 21 shares during the period. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The disclosure for this sale can be found here. 0.32% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Trading Down 0.7 %

Thermo Fisher Scientific stock opened at $546.65 on Monday. The firm has a 50-day moving average price of $533.33 and a two-hundred day moving average price of $513.55. The firm has a market capitalization of $211.21 billion, a price-to-earnings ratio of 35.65, a PEG ratio of 2.31 and a beta of 0.80. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $593.17.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last posted its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping the consensus estimate of $5.64 by $0.03. The business had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.40 earnings per share. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.57 earnings per share for the current year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback plan on Tuesday, November 14th that authorizes the company to buyback $4.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 2.2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

TMO has been the topic of several research reports. Robert W. Baird reissued an “outperform” rating and issued a $670.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, December 14th. Stifel Nicolaus decreased their price target on Thermo Fisher Scientific from $660.00 to $530.00 and set a “buy” rating for the company in a report on Thursday, October 26th. Wells Fargo & Company raised shares of Thermo Fisher Scientific from an “underweight” rating to an “equal weight” rating and set a $475.00 target price on the stock in a research report on Wednesday, October 25th. Royal Bank of Canada boosted their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Finally, Morgan Stanley lowered their target price on Thermo Fisher Scientific from $640.00 to $600.00 and set an “overweight” rating for the company in a research note on Tuesday, October 24th. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $596.00.

Get Our Latest Research Report on Thermo Fisher Scientific

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Further Reading

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.